Ozempic and Wegovy are making so much money for Novo Nordisk A/S that their cumulative sales will soon surpass the drugmaker’s entire research budget for the past three decades, undercutting a key argument for their unusually high prices.

Ozempic and Wegovy are making so much money for Novo Nordisk A/S that their cumulative sales will soon surpass the drugmaker’s entire research budget for the past three decades, undercutting a key argument for their unusually high prices.

In a high-profile showdown Tuesday with Sen. Bernie Sanders’ Senate health committee, Novo Nordisk CEO Lars Fruergaard Jørgensen will be asked to defend the drugs’ U.S. monthly list prices of $969 and $1,

Developed to treat diabetes, drugs like Ozempic now help fight obesity. Scientists newly honoured for working on them recall their findings.